EA201390413A1 - Применение миелоидных клеток в качестве биомаркеров в диагностике рака - Google Patents
Применение миелоидных клеток в качестве биомаркеров в диагностике ракаInfo
- Publication number
- EA201390413A1 EA201390413A1 EA201390413A EA201390413A EA201390413A1 EA 201390413 A1 EA201390413 A1 EA 201390413A1 EA 201390413 A EA201390413 A EA 201390413A EA 201390413 A EA201390413 A EA 201390413A EA 201390413 A1 EA201390413 A1 EA 201390413A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- biomarkers
- myeloid cells
- application
- cell carcinoma
- colorectal cancer
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38478410P | 2010-09-21 | 2010-09-21 | |
| GBGB1015765.9A GB201015765D0 (en) | 2010-09-21 | 2010-09-21 | Use of myeloid cell biomarkers for the diagnosis of cancer |
| PCT/EP2011/066397 WO2012038463A2 (en) | 2010-09-21 | 2011-09-21 | Use of myeloid cell biomarkers for the diagnosis of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201390413A1 true EA201390413A1 (ru) | 2013-07-30 |
Family
ID=43065538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201390413A EA201390413A1 (ru) | 2010-09-21 | 2011-09-21 | Применение миелоидных клеток в качестве биомаркеров в диагностике рака |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9671404B2 (https=) |
| EP (1) | EP2619585B1 (https=) |
| JP (1) | JP5970459B2 (https=) |
| KR (1) | KR20130137635A (https=) |
| CN (1) | CN103180739B (https=) |
| CA (1) | CA2811070A1 (https=) |
| EA (1) | EA201390413A1 (https=) |
| GB (1) | GB201015765D0 (https=) |
| SG (2) | SG188543A1 (https=) |
| WO (1) | WO2012038463A2 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| EP3682896A1 (en) * | 2011-04-28 | 2020-07-22 | University of Southern California | Human myeloid derived suppressor cell cancer markers |
| WO2013169913A1 (en) | 2012-05-08 | 2013-11-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Predictors of patient response to interferon-a therapy |
| WO2014159923A1 (en) * | 2013-03-13 | 2014-10-02 | Health Research, Inc. | Enhancement of vaccines |
| CN103743907B (zh) * | 2013-07-24 | 2015-04-15 | 北京大学人民医院 | 测定造血干细胞移植后患者骨髓微循环环境评测的试剂盒、系统及方法 |
| WO2015048748A1 (en) * | 2013-09-30 | 2015-04-02 | Board Of Regents, The University Of Texas System | Myeloid-derived suppressor cell-specific peptides for diagnostic and therapeutic use |
| CN103626846B (zh) * | 2013-11-08 | 2016-06-01 | 上海交通大学 | 与MDSCs特异性结合的配体多肽及药物输送系统 |
| EP3012271A1 (en) * | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| CA2990852A1 (en) * | 2015-06-26 | 2016-12-29 | Beth Israel Deaconess Medical Center, Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
| AU2016318136B2 (en) | 2015-09-02 | 2022-10-20 | Syndax Pharmaceuticals, Inc. | Selection of patients for combination therapy |
| RU2729116C2 (ru) | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| RS66062B1 (sr) | 2016-04-14 | 2024-11-29 | Ose Immunotherapeutics | Nova anti-sirpa antitela i njihove terapijske primene |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| CN107102127B (zh) * | 2017-04-07 | 2019-08-06 | 东北师范大学 | 一种人体外周血中单核样髓源抑制细胞的检测方法 |
| WO2018213665A1 (en) | 2017-05-19 | 2018-11-22 | Syndax Pharmaceuticals, Inc. | Combination therapies |
| WO2018221820A1 (ko) * | 2017-06-02 | 2018-12-06 | 이종균 | 대장 직장암 환자와 정상인의 말초혈액 내 면역세포의 분포 차이를 이용하여 면역력을 평가하고 암 발병 유무에 대한 정보를 제공하는 방법 및 이를 이용한 진단키트 |
| KR20260039788A (ko) | 2017-10-10 | 2026-03-20 | 시애틀 프로젝트 코포레이션 | 핫스팟을 이용한 신생항원 동정 |
| JP7395471B2 (ja) | 2017-10-13 | 2023-12-11 | オーセ イミュノセラピューティクス | 改変抗ＳＩＲＰａ抗体及びその使用 |
| CA3083097A1 (en) | 2017-11-22 | 2019-05-31 | Gritstone Oncology, Inc. | Reducing junction epitope presentation for neoantigens |
| KR102216725B1 (ko) * | 2017-12-29 | 2021-02-17 | 연세대학교 산학협력단 | 면역 항암 요법에 대한 치료 반응 예측 방법 |
| AU2019233577A1 (en) | 2018-03-13 | 2020-09-03 | Ose Immunotherapeutics | Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies |
| AU2019266231B2 (en) | 2018-05-07 | 2025-08-21 | Syndax Pharmaceuticals, Inc. | Selection of patients for combination therapy |
| CN110501483B (zh) * | 2019-07-25 | 2020-12-29 | 同济大学 | 一种中草药活性的检测方法 |
| TR202003833A1 (tr) | 2020-03-12 | 2021-09-21 | Hacettepe Ueniversitesi Rektoerluek | Mi̇yeloi̇d kökenli̇ baskilayici hücrelere özgü bi̇yobeli̇rteç paneli̇ |
| BR112023025194A2 (pt) | 2021-06-04 | 2024-02-27 | Boehringer Ingelheim Int | Anticorpos anti-sirp-alfa |
| CN117054649A (zh) * | 2023-08-04 | 2023-11-14 | 广州中医药大学第一附属医院 | 一种慢性萎缩性胃炎向胃癌转化标志物及其应用 |
| CN117030580B (zh) * | 2023-09-15 | 2024-07-16 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | LDNs在坏死性小肠结肠炎诊断中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US20040136973A1 (en) * | 2002-11-07 | 2004-07-15 | Eliezer Huberman | Human stem cell materials and methods |
| US8329408B2 (en) * | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
| US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| GB0820698D0 (en) * | 2008-11-12 | 2008-12-17 | Ludwig Inst Cancer Res | Uses of immunomodulators |
-
2010
- 2010-09-21 GB GBGB1015765.9A patent/GB201015765D0/en not_active Ceased
-
2011
- 2011-09-21 US US13/239,011 patent/US9671404B2/en not_active Expired - Fee Related
- 2011-09-21 EP EP11758209.8A patent/EP2619585B1/en active Active
- 2011-09-21 JP JP2013528723A patent/JP5970459B2/ja not_active Expired - Fee Related
- 2011-09-21 KR KR1020137010009A patent/KR20130137635A/ko not_active Withdrawn
- 2011-09-21 SG SG2013018973A patent/SG188543A1/en unknown
- 2011-09-21 SG SG10201510470WA patent/SG10201510470WA/en unknown
- 2011-09-21 WO PCT/EP2011/066397 patent/WO2012038463A2/en not_active Ceased
- 2011-09-21 CA CA2811070A patent/CA2811070A1/en not_active Abandoned
- 2011-09-21 CN CN201180045200.3A patent/CN103180739B/zh not_active Expired - Fee Related
- 2011-09-21 EA EA201390413A patent/EA201390413A1/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9671404B2 (en) | 2017-06-06 |
| EP2619585A2 (en) | 2013-07-31 |
| WO2012038463A2 (en) | 2012-03-29 |
| GB201015765D0 (en) | 2010-10-27 |
| JP5970459B2 (ja) | 2016-08-17 |
| WO2012038463A3 (en) | 2012-07-26 |
| CN103180739B (zh) | 2016-08-03 |
| EP2619585B1 (en) | 2017-03-01 |
| SG10201510470WA (en) | 2016-01-28 |
| US20120070461A1 (en) | 2012-03-22 |
| JP2013539857A (ja) | 2013-10-28 |
| CN103180739A (zh) | 2013-06-26 |
| KR20130137635A (ko) | 2013-12-17 |
| SG188543A1 (en) | 2013-04-30 |
| CA2811070A1 (en) | 2012-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201390413A1 (ru) | Применение миелоидных клеток в качестве биомаркеров в диагностике рака | |
| EA201390744A1 (ru) | Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований | |
| MX358541B (es) | Metodos para predecir el riesgo de desarrollar hipertension. | |
| EA201390762A1 (ru) | Новые биомаркеры для предсказания исхода противораковой иммунотерапии | |
| UA106771C2 (uk) | Моноклональні антитіла до прогастрину та їх використання | |
| WO2009037572A3 (en) | Biomarker combinations for colorectal cancer | |
| EA201400117A1 (ru) | Способы и нуклеиновые кислоты для определения прогноза у больных раком | |
| WO2012106718A3 (en) | Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment | |
| MY176706A (en) | Biomarkers and methods of treating pd-1 and pd-l1 related conditions | |
| EA201492137A1 (ru) | Антитела к cd33 и их применение в лечении рака | |
| MX357119B (es) | Microarn plasmáticos para la detección de cáncer colorrectal temprano. | |
| WO2013033609A3 (en) | Methods and compositions for the treatment and diagnosis of cancer | |
| TN2013000358A1 (en) | Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects | |
| EA201290711A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| GB2503148A (en) | Biomarker panels diagnostic methods and test kits for ovarian cancer | |
| PH12013500544A1 (en) | Breast cancer diagnostics | |
| WO2013033629A3 (en) | Methods and compositions for the treatment and diagnosis of colorectal cancer | |
| EA201590630A1 (ru) | Способы лечения и диагностики, связанные с лизилоксидазоподобным белком 2 (loxl2) | |
| WO2012027631A3 (en) | Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells | |
| EA201391423A1 (ru) | Антитела к ассоциированному с почками антигену 1 и их антигенсвязывающие фрагменты | |
| EA201590024A1 (ru) | Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток | |
| EP2619587A4 (en) | BIOMARKER FOR PREDICTING THE REPRODUCTION OF A COLORECTAL CARCINOMA | |
| WO2009015050A3 (en) | Gene expression profile for predicting ovarian cancer patient survival | |
| WO2014184679A3 (en) | Method for the prognosis and treatment of renal cell carcinoma metastasis | |
| WO2014078468A3 (en) | Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent |